KADCYLA DIN 02473224
Status: Marketed
Holder: HOFFMANN-LA ROCHE LIMITED
Available to quote
Health Canada record
| Active ingredient(s) | TRASTUZUMAB EMTANSINE 160 MG |
|---|
| Dosage form | Powder For Solution |
|---|
| Route | Intravenous |
|---|
| Schedule | SCHEDULE D; PRESCRIPTION |
|---|
| Class | Human |
|---|
| ATC | L01FD03 TRASTUZUMAB EMTANSINE |
|---|
| Original market date | 24-Oct-2018 |
|---|
| Current status date | 24-Oct-2018 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Hoffmann-La Roche Limited — licence 100006, currently licensed, last inspection rating C (2024-06-25).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing TRASTUZUMAB EMTANSINE
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02412365 | KADCYLA | HOFFMANN-LA ROCHE LIMITED | Powder For Solution | TRASTUZUMAB EMTANSINE 100 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 20515 | 2018-02-20 | Supplement to a New Drug Submission (SNDS) | LABELLING UPDATES |
Request a quote for KADCYLA
How to read a Canadian DIN record